ATE476189T1 - Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren - Google Patents

Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren

Info

Publication number
ATE476189T1
ATE476189T1 AT03707241T AT03707241T ATE476189T1 AT E476189 T1 ATE476189 T1 AT E476189T1 AT 03707241 T AT03707241 T AT 03707241T AT 03707241 T AT03707241 T AT 03707241T AT E476189 T1 ATE476189 T1 AT E476189T1
Authority
AT
Austria
Prior art keywords
animals
treatment
infectious diseases
dialysed
leukocyte extract
Prior art date
Application number
AT03707241T
Other languages
English (en)
Inventor
Nova Luis Antonio Calzada
Original Assignee
Nova Luis Antonio Calzada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Luis Antonio Calzada filed Critical Nova Luis Antonio Calzada
Application granted granted Critical
Publication of ATE476189T1 publication Critical patent/ATE476189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03707241T 2002-02-28 2003-02-26 Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren ATE476189T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA02002171A MXPA02002171A (es) 2002-02-28 2002-02-28 Extracto de leucocitos dializado en la elaboracion de un farmaco para el tratamiento de enfermedades infecciosas en animales.
PCT/MX2003/000016 WO2003072117A1 (es) 2002-02-28 2003-02-26 Extracto de leucocitos dializado para el tratamiento de enfermedades infecciosas en animales

Publications (1)

Publication Number Publication Date
ATE476189T1 true ATE476189T1 (de) 2010-08-15

Family

ID=34101965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03707241T ATE476189T1 (de) 2002-02-28 2003-02-26 Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren

Country Status (7)

Country Link
EP (1) EP1522307B1 (de)
AT (1) ATE476189T1 (de)
AU (1) AU2003208658A1 (de)
DE (1) DE60333638D1 (de)
ES (1) ES2353208T3 (de)
MX (1) MXPA02002171A (de)
WO (1) WO2003072117A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299296B6 (cs) 2006-06-13 2008-06-11 Sevapharma A.S. Lécivo transfer faktor - zpusob výroby a použití
WO2013039373A2 (es) * 2011-09-13 2013-03-21 Zepeda Lopez Hector Manuel Extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, y método de extracción, comprobación y conteo del mismo
WO2013039374A2 (es) * 2011-09-15 2013-03-21 Zepeda Lopez Hector Manuel Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como vitíligo
WO2013043032A2 (es) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Extracto dializado de leucocitos de origen bazo de tiburón para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como inmunomodulador y método de extracción, comprobación y conteo del mismo
WO2013043033A2 (es) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Método de extracción, comprobacíon de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferecia potencializado, específicamente diseñado para su uso como adyuvante potencializador de vacunas virales
WO2013058640A2 (es) * 2011-10-20 2013-04-25 Zepeda Lopez Hector Manuel Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como asma
WO2016195468A1 (es) * 2015-06-04 2016-12-08 Zepeda López Héctor Manuel Modulador de células t potencializado capaz de modular la respuesta inmune, específicamente diseñado para su uso terapeutico para tratamiento contra la enfermedad conocida como vitíligo
WO2016195469A1 (es) * 2015-06-04 2016-12-08 Zepeda López Hector Manuel Modulador de células t potencializado capaz de modular la respuesta inmune, específicamente diseñado para su uso terapéutico como ayudante potencializador de vacunas virales
US20180264050A1 (en) * 2015-06-04 2018-09-20 Hector Manuel Zepeda López (en) potentiated t-cell modulator able to modulate immune response, method for extracting, testing and counting a dialysable leucocyte extract from shark spleen to produce same, and therapeutic use thereof
MY197744A (en) * 2019-08-06 2023-07-12 Baden R&D Laboratories GmbH Composition for immunotherapy and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991182A (en) * 1971-10-19 1976-11-09 The Regents Of The University Of California Transfer factor
US4132776A (en) * 1978-02-15 1979-01-02 University Patents, Inc. Delivery of immunologically active components of transfer factor
WO1980000790A1 (en) * 1978-10-25 1980-05-01 Benzon As Alfred Transfer factor and method for producing same
US4468379A (en) * 1982-05-06 1984-08-28 Endeavor Corp. Leukocyte extracts for affecting the immune system
JPH05508847A (ja) * 1990-07-02 1993-12-09 ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン 伝達因子および使用方法

Also Published As

Publication number Publication date
MXPA02002171A (es) 2002-12-09
DE60333638D1 (de) 2010-09-16
ES2353208T3 (es) 2011-02-28
EP1522307A1 (de) 2005-04-13
WO2003072117A1 (es) 2003-09-04
AU2003208658A1 (en) 2003-09-09
EP1522307B1 (de) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
EA200201214A1 (ru) Замещенные тиоацетамиды
ATE309268T1 (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
BR0210471A (pt) Ligandos do receptor 5-ht e suas utilizações
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
BRPI0410289A (pt) ligantes do receptor de canabinóides e suas utilizações
DE60131456D1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
EA199900620A1 (ru) Фталазиноны
EA200400586A1 (ru) Замещённые тиоацетамиды
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE476189T1 (de) Dialysierter leukozytenextrakt zur behandlung von infektionskrankheiten bei tieren
DE60130998D1 (de) Ribavirin-enthaltende vakzine
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE429248T1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von virusinfektionen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
DE602005023155D1 (de) Behandlung von amyotrohper lateralsklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties